Vedolizumab.
出版信息
Aust Prescr. 2015 Dec;38(6):224-5. doi: 10.18773/austprescr.2015.081. Epub 2015 Oct 14.
Abstract
摘要
相似文献
1
Vedolizumab.
Aust Prescr. 2015 Dec;38(6):224-5. doi: 10.18773/austprescr.2015.081. Epub 2015 Oct 14.
2
Should we use vedolizumab as mono or combo therapy in ulcerative colitis?
Best Pract Res Clin Gastroenterol. 2018 Feb-Apr;32-33:27-34. doi: 10.1016/j.bpg.2018.05.002. Epub 2018 May 12.
3
Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
Expert Opin Drug Metab Toxicol. 2016 Jul;12(7):833-42. doi: 10.1080/17425255.2016.1181171. Epub 2016 May 12.
4
Vedolizumab in the Perioperative Management of Inflammatory Bowel Disease.
Curr Drug Targets. 2019;20(13):1317-1322. doi: 10.2174/1389450120666190325130142.
5
Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review.
J Crohns Colitis. 2019 Dec 10;13(12):1569-1577. doi: 10.1093/ecco-jcc/jjz095.
6
The safety of vedolizumab for the treatment of ulcerative colitis.
Expert Opin Drug Saf. 2017 Apr;16(4):501-507. doi: 10.1080/14740338.2017.1300251. Epub 2017 Mar 5.
7
Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis.
Arch Med Sci. 2016 Oct 1;12(5):1088-1096. doi: 10.5114/aoms.2016.61915. Epub 2016 Aug 24.
8
The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
J Pharmacol Exp Ther. 2009 Sep;330(3):864-75. doi: 10.1124/jpet.109.153973. Epub 2009 Jun 9.
9
Systemic Chemokine Levels with "Gut-Specific" Vedolizumab in Patients with Inflammatory Bowel Disease-A Pilot Study.
Int J Mol Sci. 2017 Aug 22;18(8):1827. doi: 10.3390/ijms18081827.
10
A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.
Clin Pharmacokinet. 2017 Nov;56(11):1287-1301. doi: 10.1007/s40262-017-0546-0.
引用本文的文献
1
Vedolizumab-induced acute interstitial nephritis with failure of steroid prophylaxis on vedolizumab rechallenge.
BMJ Case Rep. 2023 Sep 12;16(9):e254715. doi: 10.1136/bcr-2023-254715.
本文引用的文献
1
Vedolizumab as induction and maintenance therapy for Crohn's disease.
N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739.
2
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
N Engl J Med. 2013 Aug 22;369(8):699-710. doi: 10.1056/NEJMoa1215734.
Zotero 插件